Stakes Are High Ahead of FDA Panel Vote on ALS Drug
MONDAY, March 28, 2022 (HealthDay News) — Advocacy groups are pressing U.S. federal regulators to fast-track approval of an experimental drug treatment for the deadly neurological disease ALS (amyotrophic lateral sclerosis), with a decision expected this week. The push to approve the drug, so far just called AMX0035, is basedContinue Reading